Human Immunodeficiency Virus (HIV) Clinical Trial
Official title:
A Randomised, Open-label, 96-week Study Comparing the Safety and Efficacy of Three Different Combination Antiretroviral Regimens as Initial Therapy for HIV Infection.
Verified date | September 2019 |
Source | Kirby Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
In treatment naïve HIV infected subjects, combination antiretroviral therapy including efavirenz combined with tenofovir and emtricitabine will offer non-inferior antiretroviral efficacy over 48 weeks, compared to either atazanavir boosted with ritonavir combined with tenofovir and emtricitabine or tenofovir and emtricitabine combined with zidovudine and abacavir, as assessed by change from baseline plasma HIV-1 RNA viral load.
Status | Completed |
Enrollment | 329 |
Est. completion date | November 2011 |
Est. primary completion date | March 2011 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 16 Years and older |
Eligibility |
Inclusion Criteria: - HIV-1 positive by licensed diagnostic test with presumed duration of infection > 6 months from date of randomisation. - Aged > 16 years of age (or minimum age as determined by local regulations or as legal requirements dictate). - Antiretroviral treatment naïve. - Qualifying plasma HIV RNA > 2,000 copies/mL and a CD4+ T cell count of = 50 cells/µL. - No evidence of harbouring a drug resistant HIV (based upon genotypic drug testing). - Calculated creatinine clearance (CLCr) greater than or equal to 70 mL/min (Cockcroft-Gault formula). - Able to provide written informed consent. Exclusion Criteria: - The following laboratory variables, - absolute neutrophil count (ANC) < 750 cells/µL - haemoglobin < 8.0 g/dL - platelet count < 50,000 cells/µL - serum AST, ALT > 5 x upper limit of normal (ULN) - serum bilirubin > 1.5 x ULN - Pregnant or nursing mothers. - Current use of human growth hormone, testosterone or other anabolic steroid. - Current use of any prohibited medications as described in product specific information. - Acute therapy for serious infection or other serious medical illness (in the judgement of the site Principal Investigator) requiring systemic treatment and/or hospitalisation. - Patients with current alcohol or illicit substance use that in the opinion of the site Principal Investigator would conflict with any aspect of the conduct of the trial. - Patients unlikely to be able to remain in follow-up for the protocol-defined period. - Patients with known renal insufficiency. - Patients with obstructive liver disease. - Patients with intractable diarrhoea (six loose stools/day for at least seven consecutive days). - History of acute or chronic pancreatitis. - Presence of cardiomyopathy (due to any cause) or any significant cardiovascular disease, such as unstable ischemic heart disease. - Prisoners or subjects who are compulsorily detained (involuntarily incarcerated). |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Kirby Institute | The University of New South Wales |
Puls RL, Srasuebkul P, Petoumenos K, Boesecke C, Duncombe C, Belloso WH, Molina JM, Li L, Avihingsanon A, Gazzard B, Cooper DA, Emery S; Altair Study Group. Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, — View Citation
Winston A, Duncombe C, Li PC, Gill JM, Kerr SJ, Puls R, Petoumenos K, Taylor-Robinson SD, Emery S, Cooper DA; Altair Study Group. Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatme — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time-weighted Mean Change From Baseline Plasma HIV-RNA. | 48 weeks | ||
Secondary | Time Weighted Mean Change From Baseline Plasma HIV-RNA | 144 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT02511496 -
Status of Chronic Liver Disease in Hepatitis C Virus (HCV) Patients Coinfected With Human Immunodeficiency Virus (HIV) in Andalusia
|
N/A | |
Completed |
NCT02234492 -
The Effects of Statin Therapy on Coronary Flow Reserve and Inflammatory Markers in HIV-Positive Patients
|
Phase 4 | |
Completed |
NCT01685372 -
Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults
|
Phase 2 | |
Completed |
NCT02027441 -
Enhanced Prevention in Couples: Feasibility Study #2
|
N/A | |
Completed |
NCT02165202 -
Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis
|
Phase 2 | |
Completed |
NCT01615601 -
An Observational Study to Evaluate Tolerability of PREZISTA or INTELENCE in HIV-1 Infected Patients
|
Phase 4 | |
Completed |
NCT01449006 -
A Study of the Neurological Effects of Adding Maraviroc to HAART Regimen in Patients With HIV (HANDmac)
|
Phase 4 | |
Terminated |
NCT01448486 -
A Study of the Neurological Effects of Adding Raltegravir to HAART Regimen in Patients With HIV
|
Phase 4 | |
Completed |
NCT02572401 -
Steering Together in a New Direction: Reducing the Risk of HIV/STD Among African American Men
|
N/A | |
Completed |
NCT04122404 -
POC Strategies to Improve TB Care in Advanced HIV Disease
|
N/A | |
Completed |
NCT03290755 -
Sexual Hepatitis C in HIV Positive Men Who Have Sex With Men (MSM) in Bordeaux
|
||
Completed |
NCT02974998 -
Cape Town Young Women's Health CoOp
|
N/A | |
Completed |
NCT01997346 -
Multi-level Determinants of Starting ART Late: Aim 2
|
N/A | |
Completed |
NCT01516970 -
Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)
|
Phase 3 | |
Active, not recruiting |
NCT01875952 -
Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection (HIV/TBL)
|
Phase 4 | |
Completed |
NCT01199939 -
A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients
|
Phase 2 | |
Completed |
NCT03783130 -
Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults
|
Phase 1 | |
Active, not recruiting |
NCT05657106 -
Kentucky Outreach Service Kiosk (KyOSK): Reducing HIV, HCV, and Overdose Risk
|
N/A | |
Not yet recruiting |
NCT05727033 -
Extraordinarily Fun Training Project in Compulsory Secondary Education - Sexually Transmitted Infections
|
N/A | |
Completed |
NCT01053741 -
Effect of Seminal Fluid on the Colon Wall; Implications for HIV Transmission
|
N/A |